Kukje Pharma Co., Ltd.
Financials
Valuation Metrics
Kukje Pharma Co., Ltd.'s Market Cap is ₩691B. At end of 2025 it was ₩910B. Ranked #1503 of 2,436 in KR market (top 62%), #638 of 787 on KOSPI (top 81%), #166 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 71%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 69.09B KRW | KR#1,503/2,436 Sec#166/234 |
| Revenue | 177.97B KRW | KR#1,080/2,436 Sec#64/234 |
| Net Income | 5.99B KRW | KR#1,070/2,436 Sec#72/234 |
| Total Assets | 178.93B KRW | KR#1,354/2,436 Sec#101/234 |
| Net Assets | 98.50B KRW | KR#1,411/2,436 Sec#115/234 |
| Employees | 256 | KR#905/2,436 Sec#78/234 |
| Value | ||
| P/E | 11.53x | KR#794/2,436 Sec#46/234 |
| P/B | 0.70x | KR#1,143/2,436 Sec#62/234 |
| PEG | 0.75x | KR#728/2,436 Sec#47/234 |
| P/S | 0.39x | KR#745/2,436 Sec#19/234 |
| EV/EBITDA | 15.39x | KR#874/2,436 Sec#49/234 |
| FCF Yield | 3.21% | KR#986/2,436 Sec#63/234 |
| Profitability | ||
| ROE | 6.08% | KR#887/2,436 Sec#69/234 |
| ROA | 3.35% | KR#900/2,436 Sec#78/234 |
| Op. Margin | 3.29% | KR#1,162/2,436 Sec#92/234 |
| Revenue Growth | 5.96% | KR#1,121/2,436 Sec#103/234 |
| Earnings Growth | 15.42% | KR#789/2,436 Sec#50/234 |
| Financial Health | ||
| Debt Ratio | 181.64% | KR#1,547/2,436 Sec#176/234 |
| Total Debt | 30.00B KRW | KR#1,190/2,436 Sec#93/234 |
| FCF | 2.22B KRW | KR#1,064/2,436 Sec#75/234 |
| Cash | 9.08B KRW | KR#1,723/2,436 Sec#140/234 |
| Current Ratio | 1.09x | KR#1,716/2,436 Sec#173/234 |
| Net Debt/EBITDA | 3.58x | KR#999/2,436 Sec#74/234 |
| Dividend | ||
| Div. Yield | 0.94% | KR#1,157/2,436 Sec#70/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -30.16% | KR#1,574/2,436 Sec#135/234 |
| 1M Return | -3.40% | KR#1,248/2,436 Sec#125/234 |
| From 52W High | -40.31% | KR#768/2,436 Sec#54/234 |
| 1Y MDD | -41.78% | KR#583/2,436 Sec#44/234 |
| Trading | ||
| Volume | 33,805 shares | KR#1,580/2,436 Sec#155/234 |
| Foreign Own. | 4.16% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 283 KRW | KR#1,115/2,436 Sec#76/234 |
| BPS | 4,655 KRW | KR#1,496/2,436 Sec#110/234 |
Company Info
Kukje Pharma, established in 1959, is a specialized pharmaceutical manufacturing and sales company, listed on the securities market in 1975, and founded its subsidiary Kukje Care in 2011. It handles both specialized pharmaceuticals, like QRalone Eye Drops, and over-the-counter drugs, supplying products nationwide from its Seongnam headquarters and manufacturing/research facilities in Ansan. The company is actively researching 2 new drugs and 3 modified new drugs, aiming for new drug development and increased sales by developing anti-inflammatory treatments such as indole carboxamide derivatives. Kukje Pharma is headquartered in Seongnam-si, Gyeonggi-do.